Mga Batayang Estadistika
| CIK | 949699 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Pharmacyclics
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| June 10, 2015 |
PCYC / Pharmacyclics / PRICE T ROWE ASSOCIATES INC /MD/ - PCYC AS OF 05/31/2015 Passive Investment SC 13G/A 1 pcyc13gamay15.htm PCYC AS OF 05/31/2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) PHARMACYCLICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 716933106 (CUSIP Number) May 31, 2015 (Date of Event which Requires Filing of Statement) Check the appropriate box to designa |
|
| June 5, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-26658 Pharmacyclics LLC (f/k/a Pharmacyclics, Inc.) (Exact name of regis |
|
| June 1, 2015 |
PCYC / Pharmacyclics / DUGGAN ROBERT W Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 9)1 Pharmacyclics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 716933106 (CUSIP Number) ADAM W. FINERMAN |
|
| May 26, 2015 |
As filed with the Securities and Exchange Commission on May 26, 2015 As filed with the Securities and Exchange Commission on May 26, 2015 Registration No. |
|
| May 26, 2015 |
As filed with the Securities and Exchange Commission on May 26, 2015 As filed with the Securities and Exchange Commission on May 26, 2015 Registration No. |
|
| May 26, 2015 |
As filed with the Securities and Exchange Commission on May 26, 2015 As filed with the Securities and Exchange Commission on May 26, 2015 Registration No. |
|
| May 26, 2015 |
AMENDMENT NO. 1 TO LIMITED LIABILITY COMPANY OPERATING AGREEMENT OXFORD AMHERST LLC Exhibit 3.3 AMENDMENT NO. 1 TO LIMITED LIABILITY COMPANY OPERATING AGREEMENT OF OXFORD AMHERST LLC This Amendment No. 1 to the Limited Liability Company Operating Agreement (the ?Agreement?) of Oxford Amherst LLC (the ?LLC?) is entered into effective the 26th day of May, 2015 (?Effective Date?) by AbbVie Inc., a Delaware corporation, the sole member (?Member?) of the LLC. RECITALS: A. Effective Ma |
|
| May 26, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2015 PHARMACYCLICS, INC. |
|
| May 26, 2015 |
As filed with the Securities and Exchange Commission on May 26, 2015 As filed with the Securities and Exchange Commission on May 26, 2015 Registration No. |
|
| May 26, 2015 |
As filed with the Securities and Exchange Commission on May 26, 2015 S-8 POS 1 d932296ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on May 26, 2015 Registration No. 333-195926 Registration No. 333-188894 Registration No. 333-180850 Registration No. 333-174101 Registration No. 333-165409 Registration No. 333-162053 Registration No. 333-140480 Registration No. 333-131740 Registration No. 333-131739 Registration No. 333-122035 Registration No |
|
| May 26, 2015 |
As filed with the Securities and Exchange Commission on May 26, 2015 S-8 POS As filed with the Securities and Exchange Commission on May 26, 2015 Registration No. |
|
| May 26, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO AMENDMENT NO. 10 (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PHARMACYCLICS, INC. (Names of Subject Company) OXFORD AMHERST CORPORATION (Offeror) ABBVIE INC. (Parent of Offeror) (Names of Filing Persons) COMMON STOCK, $0.0001 PAR VALUE (Title |
|
| May 26, 2015 |
Good-Bye! (Leaving the SEC Website) This page is temporarily unavailable. Exhibit (a)(5)(I) PRESS RELEASE AbbVie Completes Acquisition of Pharmacyclics ? Acquisition will accelerate AbbVie?s sales and earnings growth and further diversify its revenue base. |
|
| May 26, 2015 |
Certificate of Formation Pharmacyclics LLC EX-3.1 2 a15-127041ex3d1.htm EX-3.1 Exhibit 3.1 Certificate of Formation of Pharmacyclics LLC This Certificate of Formation of Oxford Amherst LLC (the “Company”), dated March 3, 2015, is being duly executed and filed by Lauren C. Thomas, as an authorized person, to form a limited liability company under the Delaware Limited Liability Company Act 96 Del.C. § 18-101, et seq. FIRST. The name of the l |
|
| May 26, 2015 |
As filed with the Securities and Exchange Commission on May 26, 2015 As filed with the Securities and Exchange Commission on May 26, 2015 Registration No. |
|
| May 26, 2015 |
As filed with the Securities and Exchange Commission on May 26, 2015 As filed with the Securities and Exchange Commission on May 26, 2015 Registration No. |
|
| May 26, 2015 |
As filed with the Securities and Exchange Commission on May 26, 2015 As filed with the Securities and Exchange Commission on May 26, 2015 Registration No. |
|
| May 26, 2015 |
As filed with the Securities and Exchange Commission on May 26, 2015 As filed with the Securities and Exchange Commission on May 26, 2015 Registration No. |
|
| May 26, 2015 |
As filed with the Securities and Exchange Commission on May 26, 2015 As filed with the Securities and Exchange Commission on May 26, 2015 Registration No. |
|
| May 26, 2015 |
As filed with the Securities and Exchange Commission on May 26, 2015 S-8 POS 1 d932296ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on May 26, 2015 Registration No. 333-195926 Registration No. 333-188894 Registration No. 333-180850 Registration No. 333-174101 Registration No. 333-165409 Registration No. 333-162053 Registration No. 333-140480 Registration No. 333-131740 Registration No. 333-131739 Registration No. 333-122035 Registration No |
|
| May 26, 2015 |
As filed with the Securities and Exchange Commission on May 26, 2015 As filed with the Securities and Exchange Commission on May 26, 2015 Registration No. |
|
| May 26, 2015 |
As filed with the Securities and Exchange Commission on May 26, 2015 As filed with the Securities and Exchange Commission on May 26, 2015 Registration No. |
|
| May 26, 2015 |
LIMITED LIABILITY COMPANY OPERATING AGREEMENT OXFORD AMHERST LLC EX-3.2 3 a15-127041ex3d2.htm EX-3.2 Exhibit 3.2 LIMITED LIABILITY COMPANY OPERATING AGREEMENT OF OXFORD AMHERST LLC This Limited Liability Company Operating Agreement (the “Agreement”) of Oxford Amherst LLC (the “LLC”), is entered into by the sole member listed on Annex A hereto (the “Member”) effective as of the 3rd day of March, 2015. The Member has formed a limited liability company under the D |
|
| May 26, 2015 |
As filed with the Securities and Exchange Commission on May 26, 2015 Post-Effective Amendment No. 1 As filed with the Securities and Exchange Commission on May 26, 2015 Registration No. 333-187104 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-187104 UNDER THE SECURITIES ACT OF 1933 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 94-3 |
|
| May 22, 2015 |
Media: Adelle Infante (847) 938-8745 Investors: Liz Shea (847) 935-2211 EX-99.(A)(5)(H) 2 a15-115124ex99da5h.htm EX (A)(5)(H) Exhibit (a)(5)(H) PRESS RELEASE AbbVie Announces Expiration of Hart-Scott-Rodino Waiting Period for AbbVie’s Acquisition of Pharmacyclics NORTH CHICAGO, Ill., May 22, 2015 — AbbVie (NYSE: ABBV) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for AbbVie’s purchase of Pharmacyclics, Inc. has |
|
| May 22, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO AMENDMENT NO. 9 (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PHARMACYCLICS, INC. (Names of Subject Company) OXFORD AMHERST CORPORATION (Offeror) ABBVIE INC. (Parent of Offeror) (Names of Filing Persons) COMMON STOCK, $0.0001 PAR VALUE (Title o |
|
| May 21, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO AMENDMENT NO. 8 (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PHARMACYCLICS, INC. (Names of Subject Company) OXFORD AMHERST CORPORATION (Offeror) ABBVIE INC. (Parent of Offeror) (Names of Filing Persons) COMMON STOCK, $0.0001 PAR VALUE (Title o |
|
| May 21, 2015 |
Exhibit (a)(5)(G) PRESS RELEASE AbbVie Announces Offer Consideration for Acquisition of Pharmacyclics NORTH CHICAGO, Ill. |
|
| May 15, 2015 |
EX-99.(A)(5)(F) 2 a15-115122ex99da5f.htm EX-99.(A)(5)(F) Exhibit (a)(5)(F) PRESS RELEASE AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. NORTH CHICAGO, Ill., May 15, 2015 — AbbVie Inc. (“AbbVie”) (NYSE / CHX / Euronext Paris / SIX: ABBV) today announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics, |
|
| May 15, 2015 |
SC TO-T/A 1 a15-115122sctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO AMENDMENT NO. 7 (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PHARMACYCLICS, INC. (Names of Subject Company) OXFORD AMHERST CORPORATION (Offeror) ABBVIE INC. (Parent of Offeror) (Names of Filing Person |
|
| May 14, 2015 |
Exhibit 4.1 ABBVIE INC. SUPPLEMENTAL INDENTURE NO. 2 $3,000,000,000 1.800% Senior Notes due 2018 $3,750,000,000 2.500% Senior Notes due 2020 $1,000,000,000 3.200% Senior Notes due 2022 $3,750,000,000 3.600% Senior Notes due 2025 $2,500,000,000 4.500% Senior Notes due 2035 $2,700,000,000 4.700% Senior Notes due 2045 THIS SUPPLEMENTAL INDENTURE NO. 2, dated as of May 14, 2015 (the ?Supplemental Inde |
|
| May 14, 2015 |
425 1 a15-1070848k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2015 ABBVIE INC. (Exact name of registrant as specified in its charter) Delaware 001-35565 32-0375147 (State or other jurisdiction of incorporation) |
|
| May 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO AMENDMENT NO. 6 (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PHARMACYCLICS, INC. (Names of Subject Company) OXFORD AMHERST CORPORATION (Offeror) ABBVIE INC. (Parent of Offeror) (Names of Filing Persons) COMMON STOCK, $0.0001 PAR VALUE (Title o |
|
| May 8, 2015 |
425 1 a15-104904425.htm 425 Filed by AbbVie Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14d-2 of the Securities Exchange Act of 1934 Subject Company: Pharmacyclics, Inc. Form S-4 File No.: 333-202921 Set forth below are excerpts from remarks and investor slides presented by Richard A. Gonzalez, Chairman of the Board and Chief Executive Officer of Ab |
|
| May 7, 2015 |
EX-1.1 2 a15-104903ex1d1.htm EX-1.1 Exhibit 1.1 EXECUTED VERSION ABBVIE INC. $3,000,000,000 1.800% Notes due 2018 $3,750,000,000 2.500% Notes due 2020 $1,000,000,000 3.200% Notes due 2022 $3,750,000,000 3.600% Notes due 2025 $2,500,000,000 4.500% Notes due 2035 $2,700,000,000 4.700% Notes due 2045 UNDERWRITING AGREEMENT May 5, 2015 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Me |
|
| May 7, 2015 |
425 1 a15-1049038k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2015 ABBVIE INC. (Exact name of registrant as specified in its charter) Delaware 001-35565 32-0375147 (State or other jurisdiction of incorporation) |
|
| May 7, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO AMENDMENT NO. 5 (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PHARMACYCLICS, INC. (Names of Subject Company) OXFORD AMHERST CORPORATION (Offeror) ABBVIE INC. (Parent of Offeror) (Names of Filing Persons) COMMON STOCK, $0.0001 PAR VALUE (Title o |
|
| May 4, 2015 |
PCYC / Pharmacyclics 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-26658 Pharmacyc |
|
| May 1, 2015 |
Exhibit 99.1 Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates SUNNYVALE, Calif., May 1, 2015 - Pharmacyclics, Inc. (the ?Company?) (NASDAQ: PCYC) today reported financial results for the quarter ended March 31, 2015, as well as general business updates. Due to the pending merger with AbbVie Inc., no conference call will be held. Key Highlights ? Total revenu |
|
| May 1, 2015 |
Exhibit (a)(5)(e) PRESS RELEASE AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. |
|
| May 1, 2015 |
SC TO-T/A 1 a15-104901sctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO AMENDMENT NO. 4 (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PHARMACYCLICS, INC. (Names of Subject Company) OXFORD AMHERST CORPORATION (Offeror) ABBVIE INC. (Parent of Offeror) (Names of Filing Person |
|
| May 1, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2015 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 24, 2015 |
Filed by AbbVie Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14d-2 of the Securities Exchange Act of 1934 Subject Company: Pharmacyclics, Inc. Form S-4 File No.: 333-202921 Set forth below are excerpts from the AbbVie Inc. Q1 2015 earnings release conference call on April 23, 2015: Excerpts: Richard A. Gonzalez ? Chairman of the Board and Chief Execu |
|
| April 23, 2015 |
Filed by AbbVie Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14d-2 of the Securities Exchange Act of 1934 Subject Company: Pharmacyclics, Inc. Form S-4 File No.: 333-202921 PRESS RELEASE AbbVie Reports First-Quarter 2015 Financial Results ? Reports First-Quarter Adjusted EPS of $0.94, Up 32.4 Percent and Exceeding Previous Guidance Range of $0.82 to |
|
| April 17, 2015 |
SC TO-T/A 1 a15-73747sctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO AMENDMENT NO. 3 (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PHARMACYCLICS, INC. (Names of Subject Company) OXFORD AMHERST CORPORATION (Offeror) ABBVIE INC. (Parent of Offeror) (Names of Filing Persons |
|
| April 17, 2015 |
SC 14D9/A 1 d910279dsc14d9a.htm SCHEDULE 14D-9 AMENDMENT NO. 1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14D-9 (Amendment No. 1) (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 PHARMACYCLICS, INC. (Name of Subject Company) PHARMACYCLICS, INC. (Name of Persons Filing Statement) |
|
| April 17, 2015 |
AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. EX-99.(A)(5)(D) 2 a15-73747ex99da5d.htm EX (A)(5)(D) Exhibit (a)(5)(D) PRESS RELEASE AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. NORTH CHICAGO, III., April 17, 2015/PRNewswire/ — AbbVie Inc. (“AbbVie”) (NYSE / CHX / Euronext Paris / SIX: ABBV) today announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharm |
|
| April 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO AMENDMENT NO. 2 (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PHARMACYCLICS, INC. (Name of Subject Company) OXFORD AMHERST CORPORATION (Offeror) ABBVIE INC. (Parent of Offeror) (Names of Filing Persons) COMMON STOCK, $0.0001 PAR VALUE (Title of |
|
| April 8, 2015 |
Filed by AbbVie Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14d-2 of the Securities Exchange Act of 1934 Subject Company: Pharmacyclics, Inc. Form S-4 File No.: 333-202921 The following was posted on Abbvie Inc.?s website, www.abbvie.com, on April 8, 2015: REMARKABLE IMPACT ON PEOPLE?S LIVES NEWSROOM LATEST NEWS MEDIA CONTACTS PHARMACYCLICS ACQUISIT |
|
| April 8, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A (Amendment No. |
|
| March 30, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO AMENDMENT NO. 1 (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PHARMACYCLICS, INC. (Names of Subject Company) OXFORD AMHERST CORPORATION (Offeror) ABBVIE INC. (Parent of Offeror) (Names of Filing Persons) COMMON STOCK, $0.0001 PAR VALUE (Title o |
|
| March 30, 2015 |
EX-10.1 2 a15-73744ex10d1.htm EX-10.1 Exhibit 10.1 EXECUTION COPY $18,000,000,000 364—DAY BRIDGE TERM LOAN CREDIT AGREEMENT Dated as of March 27, 2015 among ABBVIE INC., as Borrower, VARIOUS FINANCIAL INSTITUTIONS, as Lenders, and MORGAN STANLEY SENIOR FUNDING, INC., as Administrative Agent BANK OF AMERICA, N.A. and THE BANK OF TOKYO-MITSUBISHI UFJ, LTD., as Syndication Agents BARCLAYS BANK PLC, B |
|
| March 30, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2015 ABBVIE INC. (Exact name of registrant as specified in its charter) Delaware 001-35565 32-0375147 (State or other jurisdiction of incorporation) (Commission file number) |
|
| March 23, 2015 |
Exhibit (a)(2) March 23, 2015 Dear Stockholder: On behalf of the board of directors of Pharmacyclics, Inc. |
|
| March 23, 2015 |
Morgan Stanley Senior Funding, Inc. 1585 Broadway New York, New York 10036 Exhibit (b)(1) STRICTLY CONFIDENTIAL Morgan Stanley Senior Funding, Inc. 1585 Broadway New York, New York 10036 The Bank of Tokyo-Mitsubishi UFJ, Ltd. 1251 Avenue of the Americas New York, New York 10020 March 4, 2015 AbbVie Inc. Bldg. AP34 1 North Waukegan Road North Chicago, Illinois 60064 Attention: Amarendra Duvvur, Vice President and Treasurer Project Oxford $18,000,000,000 Senior Unsecured 3 |
|
| March 23, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2015 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission File |
|
| March 23, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2015 ABBVIE INC. (Exact name of registrant as specified in its charter) Delaware 001-35565 32-0375147 (State or other jurisdiction of incorporation) (Commission file number) |
|
| March 23, 2015 |
SC TO-T 1 a2223850zscto-t.htm SC TO-T QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PHARMACYCLICS, INC. (Names of Subject Company) OXFORD AMHERST CORPORATION (Offeror) ABBVIE INC |
|
| March 23, 2015 |
AMENDMENT NO. 1 AGREEMENT AND PLAN OF REORGANIZATION Exhibit 2.1 AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF REORGANIZATION This AMENDMENT NO. 1 (this Amendment), dated as of March 22, 2015, to the Agreement and Plan of Reorganization (the Reorganization Agreement), dated as of March 4, 2015, is by and among AbbVie Inc., a Delaware corporation (Parent), Oxford Amherst Corporation, a Delaware corporation and a direct wholly owned subsidiary of Par |
|
| March 23, 2015 |
AMENDMENT NO. 1 AGREEMENT AND PLAN OF REORGANIZATION EX-99.(D)(2) 4 a2223850zex-99d2.htm EX-99.(D)(2) Exhibit (d)(2) AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF REORGANIZATION This AMENDMENT NO. 1 (this “Amendment”), dated as of March 22, 2015, to the Agreement and Plan of Reorganization (the “Reorganization Agreement”), dated as of March 4, 2015, is by and among AbbVie Inc., a Delaware corporation (“Parent”), Oxford Amherst Corporation, a Delaware cor |
|
| March 23, 2015 |
Exhibit (a)(5)(C) NYT?7.65? x 21? 63300 Georgeson Inc. doremus fp (212) 366-3800 Description: Oxford Amherst Corporation?Tender DoremusGraphics/63300-Oxford 03/21/2015 Proof 5 4 A registration statement relating to the securities proposed to be issued in the Offer (as defined below) has been filed with the Securities and Exchange Commission but has not yet become effective. Such securities may not |
|
| March 23, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2015 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission File |
|
| March 23, 2015 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 PHARMACYCLICS, INC. |
|
| March 17, 2015 |
EX-99.1 2 ex991to8k0738000403162015.htm Exhibit 99.1 FOR IMMEDIATE RELEASE Independent Data Monitoring Committee Unanimously Recommends Unblinding of IMBRUVICA® (ibrutinib) Phase III Combination HELIOS Trial Based on Interim Analysis Showing Significant Improvement in Progression-Free Survival in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma SUNNYVALE, CA, March 16, 2015 |
|
| March 17, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 form8k0738000403162015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2015 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction o |
|
| March 9, 2015 |
PCYC / Pharmacyclics / DUGGAN ROBERT W - AMENDMENT NO. 8 TO THE SCHEDULE 13D Activist Investment SC 13D/A 1 sc13da80738000403042015.htm AMENDMENT NO. 8 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 8)1 Pharmacyclics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per sha |
|
| March 6, 2015 |
Exhibit 4.1 SUPPORT AGREEMENT SUPPORT AGREEMENT (this ?Agreement?), dated as of March 4, 2015, is by and among AbbVie Inc. (?Parent?), Oxford Amherst Corporation, a Delaware corporation and a direct wholly owned subsidiary of Parent (?Purchaser?), and Robert W. Duggan (the ?Stockholder?). WHEREAS, each Subject Stockholder is, as of the date hereof, the record and beneficial owner (as defined in Ru |
|
| March 6, 2015 |
EX-2.1 2 d885732dex21.htm EX-2.1 Table of Contents Exhibit 2.1 AGREEMENT AND PLAN OF REORGANIZATION by and among ABBVIE INC., OXFORD AMHERST CORPORATION, OXFORD AMHERST LLC and PHARMACYCLICS, INC. dated as of March 4, 2015 Table of Contents TABLE OF CONTENTS Page ARTICLE I THE OFFER 2 Section 1.1. The Offer 2 Section 1.2. Company Actions 9 ARTICLE II THE MERGERS 11 Section 2.1. The Mergers 11 Sect |
|
| March 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2015 ABBVIE INC. (Exact name of registrant as specified in its charter) Delaware 001-35565 32-0375147 (State or other jurisdiction of incorporation) (Commission file number) |
|
| March 6, 2015 |
EX-10.1 4 d885732dex101.htm EX-10.1 Exhibit 10.1 SUPPORT AGREEMENT SUPPORT AGREEMENT (this “Agreement”), dated as of March 4, 2015, is by and among AbbVie Inc. (“Parent”), Oxford Amherst Corporation, a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”), and Robert W. Duggan (the “Stockholder”). WHEREAS, each Subject Stockholder is, as of the date hereof, the record a |
|
| March 6, 2015 |
EX-10.2 Exhibit 10.2 PHARMACYCLICS, INC. CHANGE IN CONTROL AND SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION Effective as of March 4, 2015 1. Introduction. The purpose of this Pharmacyclics, Inc. Change in Control and Severance Plan (the “Plan”) is to provide assurances of specified benefits to eligible employees of the Company and its Subsidiaries and Affiliates in the event their employment is inv |
|
| March 6, 2015 |
EX-2.1 2 d885732dex21.htm EX-2.1 Table of Contents Exhibit 2.1 AGREEMENT AND PLAN OF REORGANIZATION by and among ABBVIE INC., OXFORD AMHERST CORPORATION, OXFORD AMHERST LLC and PHARMACYCLICS, INC. dated as of March 4, 2015 Table of Contents TABLE OF CONTENTS Page ARTICLE I THE OFFER 2 Section 1.1. The Offer 2 Section 1.2. Company Actions 9 ARTICLE II THE MERGERS 11 Section 2.1. The Mergers 11 Sect |
|
| March 6, 2015 |
CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED BYLAWS OF PHARMACYCLICS, INC. EX-3.1 3 d885732dex31.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED BYLAWS OF PHARMACYCLICS, INC. The undersigned, Richard B. Love, hereby certifies that: 1. He is the duly elected Secretary of Pharmacyclics, Inc., a Delaware corporation (the “Company”). 2. Effective as of March 4, 2015, the Company’s Amended and Restated Bylaws are hereby amended to add the following ART |
|
| March 6, 2015 |
8-K 1 d885732d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2015 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of in |
|
| March 6, 2015 |
Exhibit 10.2 PHARMACYCLICS, INC. CHANGE IN CONTROL AND SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION Effective as of March 4, 2015 1. Introduction. The purpose of this Pharmacyclics, Inc. Change in Control and Severance Plan (the ?Plan?) is to provide assurances of specified benefits to eligible employees of the Company and its Subsidiaries and Affiliates in the event their employment is involuntari |
|
| March 6, 2015 |
Exhibit 2.1 AGREEMENT AND PLAN OF REORGANIZATION by and among ABBVIE INC., OXFORD AMHERST CORPORATION, OXFORD AMHERST LLC and PHARMACYCLICS, INC. dated as of March 4, 2015 TABLE OF CONTENTS Page ARTICLE I THE OFFER 2 Section 1.1. The Offer 2 Section 1.2. Company Actions 9 ARTICLE II THE MERGERS 11 Section 2.1. The Mergers 11 Section 2.2. Closing 12 Section 2.3. Effective Times 12 Section 2.4. Gove |
|
| March 6, 2015 |
SCHEDULE 14D-9 C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 PHARMACYCLICS, INC. |
|
| March 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2015 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission File |
|
| March 6, 2015 |
EX-10.1 4 d885732dex101.htm EX-10.1 Exhibit 10.1 SUPPORT AGREEMENT SUPPORT AGREEMENT (this “Agreement”), dated as of March 4, 2015, is by and among AbbVie Inc. (“Parent”), Oxford Amherst Corporation, a Delaware corporation and a direct wholly owned subsidiary of Parent (“Purchaser”), and Robert W. Duggan (the “Stockholder”). WHEREAS, each Subject Stockholder is, as of the date hereof, the record a |
|
| March 6, 2015 |
CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED BYLAWS OF PHARMACYCLICS, INC. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED BYLAWS OF PHARMACYCLICS, INC. The undersigned, Richard B. Love, hereby certifies that: 1. He is the duly elected Secretary of Pharmacyclics, Inc., a Delaware corporation (the ?Company?). 2. Effective as of March 4, 2015, the Company?s Amended and Restated Bylaws are hereby amended to add the following ARTICLE VII, Section 8: ?ARTICLE VII |
|
| March 5, 2015 |
425 1 a15-603218k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2015 ABBVIE INC. (Exact name of registrant as specified in its charter) Delaware 001-35565 32-0375147 (State or other jurisdiction of incorporation) |
|
| March 5, 2015 |
Exhibit 99.1 PRESS RELEASE AbbVie to Acquire Pharmacyclics, including its blockbuster product Imbruvica?, Creating an Industry Leading Hematological Oncology Franchise ? Adds Imbruvica? a first in class BTK inhibitor approved in multiple indications for blood cancers. ? Extensive clinical program with over 50 studies ongoing evaluating Imbruvica? as a treatment for a wide range of additional indic |
|
| March 5, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14D-9C (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 PHARMACYCLICS, INC. |
|
| March 5, 2015 |
ABBVIE’S ACQUISITION OF PHARMACYCLICS March 5, 2015 Filed by AbbVie, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14d-2 of the Securities Exchange Act of 1934 Subject Company: Pharmacyclics, Inc. Commission File No.: 000-26658 ABBVIE’S ACQUISITION OF PHARMACYCLICS March 5, 2015 2 Disclaimer and Forward-Looking Statement 2 This presentation and its contents are confidential and may not be reproduced, r |
|
| March 5, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 d885940d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2015 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of in |
|
| March 5, 2015 |
NORTH CHICAGO, Ill. and SUNNYVALE, Calif., March 4, 2015 /PRNewswire/ — AbbVie (NYSE: Exhibit 99.1 NORTH CHICAGO, Ill. and SUNNYVALE, Calif., March 4, 2015 /PRNewswire/ ? AbbVie (NYSE: ABBV) and Pharmacyclics (NASDAQ: PCYC) today announced a definitive agreement under which AbbVie will acquire Pharmacyclics, and its flagship asset Imbruvica? (ibrutinib), a highly effective treatment for hematologic malignancies. The acquisition accelerates AbbVie?s clinical and commercial presence |
|
| March 5, 2015 |
NORTH CHICAGO, Ill. and SUNNYVALE, Calif., March 4, 2015 /PRNewswire/ — AbbVie (NYSE: Exhibit 99.1 NORTH CHICAGO, Ill. and SUNNYVALE, Calif., March 4, 2015 /PRNewswire/ ? AbbVie (NYSE: ABBV) and Pharmacyclics (NASDAQ: PCYC) today announced a definitive agreement under which AbbVie will acquire Pharmacyclics, and its flagship asset Imbruvica? (ibrutinib), a highly effective treatment for hematologic malignancies. The acquisition accelerates AbbVie?s clinical and commercial presence |
|
| March 5, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2015 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commiss |
|
| February 20, 2015 |
Fourth Quarter and Full Year 2014 Earnings Exhibit 99.1 Fourth Quarter and Full Year 2014 Earnings 18-February-2015 CORPORATE PARTICIPANTS Robert W. Duggan – Chairman and CEO Manmeet Singh Soni – Chief Financial Officer Maky Zanganeh – Chief Operating Officer Shawn Cline Tomasello – Chief Commercial Officer Rainer (Ramses) M. Erdtmann – Executive Vice President of Corporate Affairs Urte Gayko – Senior VP – Regulatory Danelle James – VP, Cl |
|
| February 20, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2015 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission F |
|
| February 18, 2015 |
Exhibit 10.32 LES LABORATOIRES SERVIER Pharmacyclics, Inc. 995 E. Arques Avenue Sunnyvale, California United States of America Attention: Vice President of Business Development, Cc: Chief Financial Officer September 24, 2014 Termination of Collaboration Agreement dated April 9, 2009 between Les Laboratoires Servier and Institut de Recherches Internationales Servier (?Servier?) and Pharmacyclics, I |
|
| February 18, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 form8k0738000402182015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2015 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdictio |
|
| February 18, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-26658 Pharmacyclics, Inc. |
|
| February 18, 2015 |
PHARMACYCLICS, INC. STOCK OPTION AGREEMENT EX-10.9 2 exhibit109formofoptionagr.htm FORM OF OPTION AGREEMENT Exhibit 10.9 PHARMACYCLICS, INC. STOCK OPTION AGREEMENT RECITALS A. The Board has adopted the Plan for the purpose of retaining the services of selected Employees, Consultants and members of the Board who provide services to the Company (or any Subsidiary). B. Participant is to render valuable services to the Company (or a Subsidiary |
|
| February 18, 2015 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Pharmacyclics Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Updates - Reaffirms 2015 U.S. Product Revenue Guidance - Sunnyvale, CA, February 18, 2015 - Pharmacyclics, Inc. (the “Company”) (NASDAQ: PCYC) today reported financial results for the quarter and year ended December 31, 2014, as well as commercial, regulatory and clini |
|
| February 18, 2015 |
Exhibit 10.33 LES LABORATOIRES SERVIER Pharmacyclics, Inc. 995 E. Arques Avenue Sunnyvale, California UNITED STATES OF AMERICA For the attention of : Vice President of Business Development Cc: Chief Financial Officer Subject: Servier?s termination commitments September 24, 2014 Dear Sirs, In the spirit of enabling a smooth transition of our relationship following the termination of our collaborati |
|
| February 18, 2015 |
Exhibit 21.1 SUBSIDIARIES Pharmacyclics Cayman Ltd. Cayman Islands Pharmacyclics Switzerland GmbH Switzerland Pharmacyclics (Europe) Ltd. Ireland Pharmacyclics (Shanghai) Management Consulting Service Limited |
|
| February 18, 2015 |
EX-10.34 5 exhibit1034cooofferletter.htm CCO OFFER LETTER Exhibit 10.34 Aug 7, 2014 Shawn Tomasello Dear Shawn, On behalf of the Company's Board of Directors, I am pleased to make you an offer to join the Company as its Chief Commercial Officer. The purpose of this letter agreement (the "Agreement") is to set forth the terms of your proposed employment with the Company, including compensation and |
|
| February 17, 2015 |
PCYC / Pharmacyclics / BAKER FELIX - SC 13G/A Passive Investment SC 13G/A 1 v401300sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 6)* Pharmacyclics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 716933106 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of this Statement) Check the appropriate b |
|
| February 17, 2015 |
to Schedule 13G Joint Filing Agreement EX-99.II 3 d868329dex99ii.htm EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 13, 2015 in connection with their beneficial ownership of Pharmacyclics, Inc. Columbia Management Investment Advisers, LLC authorizes Ameriprise Financial, Inc. to execute the Schedule 13G to which |
|
| February 17, 2015 |
PCYC / Pharmacyclics S-8 POS - - As filed with the Securities and Exchange Commission on February 13, 2015 Registration No. |
|
| February 17, 2015 |
PCYC / Pharmacyclics S-8 POS - - S-8 POS 1 s8pos07380004d02172015.htm As filed with the Securities and Exchange Commission on February 13, 2015 Registration No. 333-21551 Registration No. 333-30026 Registration No. 333-55592 Registration No. 333-81870 Registration No. 333-115174 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO Form S-8 Registration Statement No. 333-81870 POS |
|
| February 17, 2015 |
PCYC / Pharmacyclics S-8 POS - - As filed with the Securities and Exchange Commission on February 13, 2015 Registration No. |
|
| February 17, 2015 |
EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. |
|
| February 17, 2015 |
PCYC / Pharmacyclics / AMERIPRISE FINANCIAL INC - SC 13G Passive Investment SC 13G 1 d868329dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities and Exchange Act of 1934 Pharmacyclics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 716933106 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 17, 2015 |
PCYC / Pharmacyclics S-8 POS - - S-8 POS 1 s8pos07380004a02172015.htm As filed with the Securities and Exchange Commission on February 13, 2015 Registration No. 333-21551 Registration No. 333-30026 Registration No. 333-55592 Registration No. 333-81870 Registration No. 333-115174 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO Form S-8 Registration Statement No. 333-81870 POS |
|
| February 17, 2015 |
PCYC / Pharmacyclics S-8 POS - - As filed with the Securities and Exchange Commission on February 13, 2015 Registration No. |
|
| February 13, 2015 |
PCYC / Pharmacyclics / PRICE T ROWE ASSOCIATES INC /MD/ - PCYC AS OF 12/31/2014 Passive Investment SC 13G/A 1 pcyc13gadec14.htm PCYC AS OF 12/31/2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) PHARMACYCLICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 716933106 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of Statement) Check the appropriate box to de |
|
| February 2, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 form8k0738000401292015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2015 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction |
|
| February 2, 2015 |
EX-99.1 2 ex991to8k0738000401292015.htm Exhibit 99.1 SUNNYVALE, Calif., Jan. 29, 2015 - Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has granted single-agent IMBRUVICA® (ibrutinib) regular (full) approval in all lines of therapy as the first and only treatment for patients with Waldenstrom’s macroglobulinemia (WM), a rare, indolent type of B-c |
|
| January 23, 2015 |
8-K 1 form8k0738000401162015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2015 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction |
|
| January 20, 2015 |
8-K 1 pcyc8kjan202015.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 20, 2015 PHARMACYCLICS, INC. (Exact Name of Registrant as specified in Charter) Delaware 000-26658 94-3148201 (State or Other Jurisdiction o |
|
| January 13, 2015 |
Exhibit 99.1 Pharmacyclics Announces Preliminary 2014 U.S. Net Product Revenue Results and 2015 U.S. Net Product Revenue Outlook SUNNYVALE, Calif., Jan. 12, 2015– Pharmacyclics, Inc. (NASDAQ: PCYC) today provided its preliminary unaudited 2014 U.S. net product revenue results and 2015 U.S. net product revenue outlook at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. For th |
|
| January 13, 2015 |
EX-99.1 2 ex991to8k0738000401122015.htm Exhibit 99.1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 |
|
| January 13, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2015 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 13, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 form8k0738000401122015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2015 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction |
|
| December 11, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 5, 2014 PHARMACYCLICS, INC. (Exact Name of Registrant as specified in Charter) Delaware 000-26658 94-3148201 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| December 11, 2014 |
EX-99.1 2 ex991to8k07380004a12092014.htm PHARMACYCLICS ANNOUNCES LAUNCH OF INFORMCLL REGISTRY FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS Exhibit 99.1 FOR IMMEDIATE RELEASE Pharmacyclics Announces Launch of informCLL™ Registry for Chronic Lymphocytic Leukemia (CLL) Patients U.S.-Based Registry Will Enhance Clinical Knowledge of and Explore Treatment Options for CLL Patients SUNNYVALE, CA, Dece |
|
| December 11, 2014 |
IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma EX-99.2 3 ex992to8k07380004a12092014.htm IMBRUVICA (IBRUTINIB) DATA SUGGESTS PROMISE IN MULTIPLE MYELOMA Exhibit 99.2 FOR IMMEDIATE RELEASE IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma · Note: This press release corresponds to abstract 31. SAN FRANCISCO, CA, December 6, 2014 – New IMBRUVICA® (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc. (NASDAQ: PCYC) du |
|
| December 11, 2014 |
Exhibit 99.4 FOR IMMEDIATE RELEASE Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL) Data Show 84% Progression-Free Survival Rate at One Year and Improvement in Quality of Life · Note: This press release corresponds to abstracts 327, 3331 and 4696. SAN FRANCISCO, CA, December 8, 2014 – Pharmacycl |
|
| December 11, 2014 |
Exhibit 99.3 FOR IMMEDIATE RELEASE IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy · Note: This press release corresponds to abstracts 627 and 1998. SAN FRANCISCO, CA, December 8, 2014 – New IMBRUVICA® (ibrutinib) Phase II data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today demonstrates its potential utility as a combin |
|
| December 11, 2014 |
EX-99.5 6 ex995to8k07380004a12092014.htm IMBRUVICA (IBRUTINIB) DATA DEMONSTRATES SAFETY AND DURABILITY OF RESPONSE AT TWO-YEAR FOLLOW-UP IN MANTLE CELL LYMPHOMA Exhibit 99.5 FOR IMMEDIATE RELEASE IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in Mantle Cell Lymphoma · Note: This press release corresponds to abstracts 4453 and 4471 SAN FRANCISCO, CA |
|
| December 2, 2014 |
Exhibit 99.1 New IMBRUVICA® (ibrutinib) Application Accepted by European Medicines Agency for Waldenstrom’s Macroglobulinemia Filing completed less than two months after first European approval for IMBRUVICA® SUNNYVALE, Calif., Dec. 1, 2014 - Pharmacyclics, Inc. (PCYC) today announced the acceptance of a Type II variation application for IMBRUVICA® (ibrutinib) by the European Medicines Agency (EMA |
|
| December 2, 2014 |
Financial Statements and Exhibits, Other Events 8-K 1 form8k0738000412012014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction |
|
| November 28, 2014 |
8-K 1 form8k0738000411242014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdictio |
|
| November 12, 2014 |
Exhibit 99.1 Third Quarter 2014 Earnings 04-November-2014 CORPORATE PARTICIPANTS Rainer (Ramses) M. Erdtmann – Executive Vice President of Corporate Affairs Robert W. Duggan – Chairman and CEO Manmeet Singh Soni – Chief Financial Officer Maky Zanganeh – Chief Operating Officer Shawn Cline Tomasello – Chief Commercial Officer Urte Gayko – Senior VP of Global Regulatory Affairs Maria Fardis – Chief |
|
| November 12, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 form8k07380004b11042014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdictio |
|
| November 7, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 pcyc20140930q3x10-q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Com |
|
| November 6, 2014 |
Financial Statements and Exhibits, Other Events 8-K 1 form8k07380004b11062014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdictio |
|
| November 6, 2014 | ||
| November 6, 2014 |
Exhibit 99.1 FOR IMMEDIATE RELEASE IMBRUVICA® (ibrutinib) Data to be Presented Across Multiple Histologies, Including in Eight Oral Presentations, at 2014 American Society of Hematology (ASH) Annual Meeting More than 37 IMBRUVICA Data Abstracts Will be Presented SUNNYVALE, CA, November 6, 2014 – Pharmacyclics, Inc. (NASDAQ: PCYC) today announced a broad array of new IMBRUVICA® (ibrutinib) data acr |
|
| November 6, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 form8k0738000411062014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2014 PHARMACYCLICS, INC (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction |
|
| November 6, 2014 |
American Society of Hematology (ASH) Annual Meeting: Exhibit 99.1 American Society of Hematology (ASH) Annual Meeting: San Francisco, California; December 6 - 9, 2014 Title Presenting Author Presentation Date/Time Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results Dr. Vij Session Name: Myeloma: Therapy, excluding Transplantation I Date: Saturday, Decem |
|
| November 4, 2014 |
Pharmacyclics Reports Third Quarter 2014 Financial Results and Provides Clinical Program Update Exhibit 99.1 FOR IMMEDIATE RELEASE Pharmacyclics Reports Third Quarter 2014 Financial Results and Provides Clinical Program Update Sunnyvale, CA, November 4, 2014 - Pharmacyclics, Inc. (the “Company”) (NASDAQ: PCYC) today reported financial results for the third quarter and nine months ended September 30, 2014, as well as commercial, regulatory and clinical updates. Key Highlights · Net product re |
|
| November 4, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 form8k0738000411042014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction |
|
| October 20, 2014 |
Financial Statements and Exhibits, Other Events 8-K 1 pharmacyclics8koct172014.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 17, 2014 PHARMACYCLICS, INC. (Exact Name of Registrant as specified in Charter) Delaware 000-26658 94-3148201 (State or Other Juris |
|
| October 20, 2014 |
IMBRUVICA® (ibrutinib) Now Approved in Europe for Treatment of Two Blood Cancers Exhibit 99.1 IMBRUVICA® (ibrutinib) Now Approved in Europe for Treatment of Two Blood Cancers SUNNYVALE, Calif., Oct. 17, 2014 - Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the European Commission (EC) has granted marketing approval for IMBRUVICA® (ibrutinib) throughout the 28 member states of the European Union (EU). IMBRUVICA, a first-in-class, oral, once-daily, non-chemotherapy trea |
|
| September 30, 2014 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 form8k0738000409242014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdicti |
|
| September 30, 2014 |
Pharmacyclics and Servier Agree to Conclude Pan-HDAC Inhibitor Collaboration EX-99.1 2 ex991to8k0738000409242014.htm Exhibit 99.1 FOR IMMEDIATE RELEASE Pharmacyclics and Servier Agree to Conclude Pan-HDAC Inhibitor Collaboration Sunnyvale, CA, and Suresnes, France, September 25, 2014 – Pharmacyclics, Inc. (NASDAQ: PCYC) and Servier today announced that they have mutually and amicably ended their collaboration pertaining to the ex-U.S. development of Pharmacyclics’ pan-HDAC |
|
| August 29, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 14, 2014 | ||
| August 14, 2014 |
Commercial Manufacturing Agreement (the “Agreement”) Exhibit 10.1 EXECUTION VERSION Commercial Manufacturing Agreement (the “Agreement”) by and between Lonza Sales Ltd. Münchensteinerstrasse 38 CH4002 Basel Switzerland - hereinafter “Lonza” – and Pharmacyclics, Inc. 995 E. Argues Avenue Sunnyvale, CA 94085 U.S.A - hereinafter “Pharmacyclics” - Effective as of February 5, 2013 (the “Effective Date”) [**] Certain information in this document has been |
|
| August 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2013 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorpor |
|
| August 14, 2014 |
Exhibit 10.2 AMENDMENT ONE TO COMMERCIAL MANUFACTURING AGREEMENT This first amendment (the “Amendment”) to that certain Commercial Manufacturing Agreement (the “Agreement”) effective as of February 5, 2013 by and between Pharmacyclics, Inc. a corporation organized under the laws of State of Delaware and having its principal place of address 995 E. Arques Avenue, Sunnyvale, CA 94085 (“Pharmacyclics |
|
| August 8, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2014 PHARMACYCLICS, INC. (Exact Name of Registrant as specified in Charter) Delaware 000-26658 94-3148201 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 8, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-26658 Pharmacycl |
|
| August 4, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission File |
|
| August 4, 2014 |
Exhibit 99.1 Second Quarter 2014 Earnings 31-July-2014 CORPORATE PARTICIPANTS Ramses M. Erdtmann – Executive Vice President of Corporate Affairs Robert W. Duggan – Chairman and CEO Manmeet Singh Soni – Chief Financial Officer Maky Zanganeh – Chief Operating Officer Matt Outten – VP, Commercial Operations Jesse McGreivy MD – Chief Medical Officer Urte Gayko – Senior VP of Global Regulatory Affairs |
|
| August 4, 2014 |
begin 644 ex992to8k07380004b07312014.pdf M)5!$1BTQ+C0-)>+CS],-"C$Q,3D@,"!O8FH-/#PO3&EN96%R:7IE9"`Q+TP@ M-S@P,S`Q+T\@,3$R,B]%(#$R,C8R."].(#(S+U0@-S4W.#-J<5&M,$UD4NZTI<%SH!: M"=FT0Z6%F%@L:#6P*6W%B@@-4A.?*8AM-/Y`PEHQQ@PLR-0'J:\0481J$)48 MJ<1$34Q\1XT:<-FX/UB#0J*;330^?JB]G8LB-E>R8GYW[G.?<<^[D7``, MH'!#`1015TO19.J).V`2=,>$(P-/4V;!U*&'6K5;L$\I'W# M#.+7F[Y`6>W&GJ+K+9U#\4^.>VF#)+[NV,F\,II'[6/6+]U1L>98>J4L6 |
|
| July 31, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission File |
|
| July 31, 2014 |
Exhibit 99.2 U.S. FDA Grants Regular (Full) Approval for IMBRUVICA® for Two Indications Previously Treated Chronic Lymphocytic Leukemia (CLL) Based on Statistically Significant Progression-Free and Overall Survival Benefits Del 17P CLL, Only FDA-Approved Agent SUNNYVALE, Calif., July 28, 2014 - Pharmacyclics, Inc. (PCYC) today announced that the U.S. Food and Drug Administration (FDA) has granted |
|
| July 31, 2014 |
Exhibit 99.1 IMBRUVICA FDA Approval Call 28-July-2014 CORPORATE PARTICIPANTS Robert W. Duggan – Chairman and CEO Maky Zanganeh – Chief Operating Officer Jesse McGreivy MD – Chief Medical Officer Maria Fardis – Chief Oncology Operations & Alliances Ramses M. Erdtmann – Executive Vice President of Corporate Affairs Urte Gayko – Senior VP of Global Regulatory Affairs Matt Outten – VP, Commercial Oper |
|
| July 31, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 form8k0738000407282014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of |
|
| July 31, 2014 |
Pharmacyclics Reports Second Quarter 2014 Results Pharmacyclics Reports Second Quarter 2014 Results - IMBRUVICA Net Product Revenue Increased to $109. |
|
| June 5, 2014 |
EX-99.5 6 ex995to8k0738005312014.htm PRESENATION - RANDOMIZED COMPARISON Exhibit 99.5 |
|
| June 5, 2014 |
Exhibit 99.1 IMBRUVICA® (ibrutinib) Significantly Improves Progression Free Survival, Overall Survival and Overall Response as compared to Ofatumumab in Patients with Previously Treated CLL/SLL in its First Phase III study Results from Phase III RESONATE™ Trial Published in an Online First Edition of the New England Journal of Medicine SUNNYVALE, Calif., May 31, 2014 - Pharmacyclics, Inc. (NASDAQ: |
|
| June 5, 2014 |
Exhibit 99.4 |
|
| June 5, 2014 |
IMBRUVICA® (ibrutinib) Shows Durable, Long-Term Responses for Patients with CLL Exhibit 99.3 IMBRUVICA® (ibrutinib) Shows Durable, Long-Term Responses for Patients with CLL SUNNYVALE, Calif., May 31, 2014 - Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that IMBRUVICA® (ibrutinib) will be featured in an oral presentation highlighting long-term responses to treatment, with up to three years of follow up in 132 patients with treatment naive or relapsed/refractory chronic ly |
|
| June 5, 2014 |
EX-99.2 3 ex992to8k0738005312014.htm PRESS RELEASE - IMBRUVICA SHOWS DURABLE Exhibit 99.2 IMBRUVICA® (ibrutinib) Combination with anti CD20 Antibody Shows Compelling Results in Heavily Pretreated Patients with CLL and Related Diseases SUNNYVALE, Calif., May 31, 2014 - Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that IMBRUVICA®(ibrutinib) in combination with the anti-CD20 antibody, ofatumuma |
|
| June 5, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 form8k0738005312014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of inc |
|
| May 23, 2014 |
8-K 1 form8k0738000405202014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of |
|
| May 16, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 16, 2014 |
Exhibit 99.1 Pharmacyclics Highlights Important New Data for IMBRUVICA® (ibrutinib) in B-Cell Malignancies Initial Presentation of Phase III RESONATETM study and updated results in CLL of single agent IMBRUVICA and also CD20 combination to be presented during ASCO May 30 - Jun 3, 2014 Note: This release corresponds to abstracts 7014, 7009, TPS8611^, TPS8615^ Sunnyvale, Ca, May 14, 2014 - Pharmacyc |
|
| May 14, 2014 |
8-K 1 form8k0738005082014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of inco |
|
| May 14, 2014 |
PHARMACYCLICS, INC. 2014 Equity Incentive Award Plan Article 1 Establishment and Purpose EX-10.1 2 ex101to8k0738005082014.htm Exhibit 10.1 PHARMACYCLICS, INC. 2014 Equity Incentive Award Plan Article 1 Establishment and Purpose 1.1 Establishment of the Plan. Pharmacyclics, Inc., a Delaware corporation (the “Company” or “Pharmacyclics”), hereby establishes an incentive compensation plan (the “Plan”), as set forth in this document. 1.2 Purpose of the Plan. The purpose of the Plan is to |
|
| May 13, 2014 |
S-8 1 s80738000405132014.htm As filed with the Securities and Exchange Commission on May 13, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 PHARMACYCLICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 94-3148201 (State or Other Jurisdiction of Incorporation or |
|
| May 13, 2014 |
PHARMACYCLICS, INC. 2014 Equity Incentive Award Plan Article 1 Establishment and Purpose Exhibit 4.1 PHARMACYCLICS, INC. 2014 Equity Incentive Award Plan Article 1 Establishment and Purpose 1.1 Establishment of the Plan. Pharmacyclics, Inc., a Delaware corporation (the “Company” or “Pharmacyclics”), hereby establishes an incentive compensation plan (the “Plan”), as set forth in this document. 1.2 Purpose of the Plan. The purpose of the Plan is to promote the success and enhance the va |
|
| May 8, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-26658 Pharmacyc |
|
| May 7, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 7, 2014 |
EX-99.1 2 ex991to8k07380a05022014.htm Exhibit 99.1 First Quarter 2014 Earnings 02-May-2014 CORPORATE PARTICIPANTS Ramses M. Erdtmann – SVP, Investor Relations& Administration Manmeet Singh Soni – Chief Financial Officer Robert W. Duggan – Chairman and CEO Matt Outten – VP, Commercial Operations Jesse McGreivy MD – Chief Medical Officer Maria Fardis – Chief Oncology Operations & Alliances CONFERENC |
|
| May 2, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 2, 2014 |
Pharmacyclics Reports First Quarter 2014 Results Exhibit 99.1 Pharmacyclics Reports First Quarter 2014 Results First full quarter after launch of IMBRUVICATM net product revenue of $56.2 million SUNNYVALE, CA, May 2, 2014 Pharmacyclics, Inc. (the “Company”) (Nasdaq: PCYC) today reported financial results and recent developments for the quarter ended March 31, 2014. Financial Results for the Quarter Ended March 31, 2014 GAAP and Non-GAAP net inco |
|
| April 25, 2014 |
DEFA14A 1 defa14a20738004242014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o P |
|
| April 25, 2014 |
DEFA14A 1 defa14a0738004242014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Pr |
|
| April 21, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission File |
|
| April 21, 2014 |
Exhibit 99.1 Pharmacyclics Announces Presentation of Phase III and Long Term Follow Up Data on IMBRUVICA™ in Chronic Lymphocytic Leukemia (CLL) at ASCO SUNNYVALE, Calif., April 21, 2014 - Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that data from the Phase III PCYC-1112 (RESONATE™) study of single agent IMBRUVICA™ (ibrutinib) vs. ofatumumab, an established therapy in relapsed refractory CLL |
|
| April 8, 2014 |
8-K 1 form8k0738004022014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of in |
|
| April 8, 2014 |
Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with Phase III CLL Study Data EX-99.1 2 ex991to8k0738004082014.htm Exhibit 99.1 Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with Phase III CLL Study Data SUNNYVALE, Calif., April 8, 2014 - Pharmacyclics, Inc. (PCYC) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA), based on data from the randomized, multi-center, open-label P |
|
| April 8, 2014 |
Prepared by R.R. Donnelley Financial - Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14a Information Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ |
|
| April 8, 2014 |
Financial Statements and Exhibits, Other Events - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission File |
|
| March 27, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission File |
|
| March 20, 2014 |
O L S H A N PARK AVENUE TOWER ● 65 EAST 55TH STREET ● NEW YORK, NEW YORK 10022 TELEPHONE: 212. |
|
| March 4, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2014 PHARMACYCLICS, INC. (Exact Name of Registrant as specified in Charter) Delaware 000-26658 94-3148201 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 26, 2014 |
Exhibit 21.1 SUBSIDIARIES Pharmacyclics Cayman Ltd. Cayman Islands Pharmacyclics Switzerland GmbH Switzerland Pharmacyclics (Europe) Ltd. Ireland Pharmacyclics (Shanghai) Management Consulting Service Limited |
|
| February 26, 2014 |
AMENDMENT TO THE PHARMACYCLICS INC. EMPLOYEE STOCK PURCHASE PLAN EX-10.39 3 a1039secondamendmenttothep.htm ESPP AMENDMENT 2 Exhibit 10.39 AMENDMENT TO THE PHARMACYCLICS INC. EMPLOYEE STOCK PURCHASE PLAN In accordance with Subsection A of Article IX of the Pharmacyclics, Inc. Employee Stock Purchase Plan (“Plan”), the Plan is hereby amended effective May 9, 2013 to read as follows: 1.Subsection A of Article X of the Plan shall be amended by substituting a semico |
|
| February 26, 2014 |
BINDING NOTICE TO LANDLORD TO EXERCISE EXPANSION OPTION Exhibit 10.42 Via Certified Mail John Hessler Patson?s Press 970 Stewart Drive Sunnyvale, California 94085 Re: Commercial Lease (?Lease?) between John G. and Theresa L. Hessler as Trustees of the Hessler 2007 Revocable Trust, Mark Dellamano, John Dellamano and Joseph Dellamano, as tenants-in-common (?Landlord?) and Pharmacyclics, Inc. (?Tenant?) for those premises located at 968-970 Stewart Drive, |
|
| February 26, 2014 |
Exhibit 10.40 Jacqueline A. Denning 425 Market Street, Suite 1050 San Francisco, CA 94105 Tel 415 536-1068 Fax 415 536-1098 Fransheska Saldana Pharmacyclics, Inc. 995 E. Argues Ave. Sunnyvale, CA 94085 RE: Amendment No. 8 to the Lease Agreement between Metropolitan Life Insurance company and Pharmacyclics Inc. Dear Ms. Saldana, Enclosed is your executed copy of the above referenced Amendment. Addi |
|
| February 26, 2014 |
FIRST AMENDMENT TO THE PHARMACYCLICS INC. EMPLOYEE STOCK PURCHASE PLAN Exhibit 10.38 FIRST AMENDMENT TO THE PHARMACYCLICS INC. EMPLOYEE STOCK PURCHASE PLAN In accordance with Subsection A of Article IX of the Pharmacyclics, Inc. Employee Stock Purchase Plan (?Plan?), the Plan is hereby amended effective May 9, 2013 to read as follows: 1.Subsection A of Article VI of the Plan shall be amended by substituting 1,800,000 for 1,500,000. PHARMACYCLICS, INC. /s/ Manmeet S. |
|
| February 26, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K 10-K 1 a20131231-10xk.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-26 |
|
| February 26, 2014 |
968-970 STEWART DRIVE, SUNNYVALE, CA COMMERCIAL LEASE SUMMARY Exhibit 10.41 968-970 STEWART DRIVE, SUNNYVALE, CA COMMERCIAL LEASE SUMMARY The information contained in this ?Commercial Lease Summary? is incorporated into the terms of the attached ?Commercial Lease? (the ?Lease?). I. LANDLORD: John G. and Theresa L. Hessler as Trustees of the Hessler 2007 Revocable Trust; Mark Dellamano, John Dellamano and Joseph Dellamano, as Tenants in Common II. TENANT: Pha |
|
| February 26, 2014 |
PHARMACYCLICS, INC. Restricted Stock Unit Agreement Granted under Amended and Restated 2004 Equity Incentive Award Plan (?Plan?) NOTICE OF GRANT This Restricted Stock Unit Agreement (this ?Agreement?) is made as of the Agreement Date between Pharmacyclics, Inc. (the ?Company?), a Delaware corporation, and the Participant. I. Agreement Date Date: II. Participant Information Participant: Participant |
|
| February 25, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission F |
|
| February 25, 2014 |
Fourth Quarter and Full Year 2013 Earnings Exhibit 99.1 Fourth Quarter and Full Year 2013 Earnings 20-Feb-2014 CORPORATE PARTICIPANTS Ramses M. Erdtmann - SVP, Investor Relations Manmeet Singh Soni – Chief Financial Officer Robert W. Duggan - Chairman and CEO Paula Boultbee - EVP, Sales and Marketing Jesse McGreivy MD - Chief Medical Officer Urte Gayko - SVP, Global Regulatory Affairs Matt Outten – Sr. Director, Market Access CONFERENCE CA |
|
| February 20, 2014 |
Exhibit 99.1 Pharmacyclics Reports Fourth Quarter and Full Year 2013 Results Company launches its first product, IMBRUVICATM, and records net product revenue of $13.6 million SUNNYVALE, CA, February 20, 2014 - Pharmacyclics, Inc. (the “Company”) (Nasdaq: PCYC) today reported financial results and recent developments for the quarter and year ended December 31, 2013. Financial Results for the Quarte |
|
| February 20, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 form8k0738002202014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction o |
|
| February 14, 2014 |
Exhibit 99.1 IMBRUVICATM CLL Approval Call 12-Feb-2014 CORPORATE PARTICIPANTS Ramses M. Erdtmann - SVP, Investor Relations Robert W. Duggan - Chairman and CEO Paula Boultbee - EVP, Sales and Marketing Jesse McGreivy MD - Chief Medical Officer Urte Gayko - SVP, Global Regulatory Affairs CONFERENCE CALL PARTICIPANTS Robyn Karnauskas John Chung Deutsche Bank – Analyst RBC Capital Markets – Analyst Mi |
|
| February 14, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission F |
|
| February 14, 2014 |
PCYC / Pharmacyclics / BAKER FELIX - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2014 |
EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Pharmacyclics, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. February 14, 2014 BAKER BROS. ADVISORS LP By: Baker Bros. Advisors (GP) LLC, its ge |
|
| February 12, 2014 |
EX-99.1 2 ex991to8k0738002122014.htm Exhibit 99.1 U.S. Food and Drug Administration Approves IMBRUVICATM (ibrutinib) as a Single Agent for Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy SUNNYVALE, CA, February 12, 2014 - Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib) as |
|
| February 12, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission F |
|
| February 11, 2014 |
PCYC / Pharmacyclics / PRICE T ROWE ASSOCIATES INC /MD/ - PCYC AS OF 12/31/2013 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* PHARMACYCLICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 716933106 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule i |
|
| February 5, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 13, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2014 PHARMACYCLICS, INC. (Exact Name of Registrant as specified in Charter) Delaware 000-26658 94-3148201 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 7, 2014 |
Financial Statements and Exhibits, Other Events - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2014 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 7, 2014 |
Exhibit 99.1 Independent Data Monitoring Committee recommends Phase III study of IMBRUVICA™ (ibrutinib) versus ofatumumab be stopped early based on statistically significant improvement in progression free survival and overall survival SUNNYVALE, Calif., Jan. 7, 2014 - Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that an Independent Data Monitoring Committee (IDMC) unanimously recommended th |
|
| December 11, 2013 |
Exhibit 99.4 |
|
| December 11, 2013 |
EX-99.1 2 ex991to8k0738012102013.htm Exhibit 99.1 |
|
| December 11, 2013 |
EX-99.5 6 ex995to8k0738012102013.htm Exhibit 99.5 |
|
| December 11, 2013 |
Exhibit 99.1 Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies Clinical Presentation in Waldenström’s Macroglobulinemia Deemed “Best of ASH” New Orleans, LA, December 10, 2013 - Pharmacyclics, Inc. (NASDAQ: PCYC) today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Soci |
|
| December 11, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 form8k20738012102013.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2013 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction |
|
| December 11, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2013 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission F |
|
| December 11, 2013 |
Exhibit 99.3 |
|
| December 11, 2013 |
EX-99.6 7 ex996to8k0738012102013.htm Exhibit 99.6 |
|
| December 11, 2013 |
EX-99.2 3 ex992to8k0738012102013.htm Exhibit 99.2 |
|
| December 10, 2013 |
Financial Statements and Exhibits, Other Events - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2013 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 10, 2013 |
Ibrutinib Frontline Chronic Lymphocytic Leukemia Study Results Published in The Lancet Oncology Exhibit 99.1 Ibrutinib Frontline Chronic Lymphocytic Leukemia Study Results Published in The Lancet Oncology - Estimated progression-free survival at 24 months was 96.3 percent in this Phase 1b/2 trial- SUNNYVALE, CA, December 09 2013 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that The Lancet Oncology published results of a study evaluating ibrutinib in previously untreated elderly patient |
|
| November 20, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2013 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission F |
|
| November 19, 2013 |
BUILD-OUT AND COMMERCIAL SUPPLY AGREEMENT EX-10.3 4 ex103to8k0738011192013.htm Exhibit 10.3 BUILD-OUT AND COMMERCIAL SUPPLY AGREEMENT This Build-Out and Commercial Supply Agreement (“Agreement”) is made as of this 1st day of May, 2013 (“Effective Date”), by and between Pharmacyclics, Inc., a Delaware corporation, with a place of business at 995 East Arques Avenue, Sunnyvale, CA 94085 (“Client”), and Catalent CTS, LLC, a Delaware limited l |
|
| November 19, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2013 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission F |
|
| November 19, 2013 |
Exhibit 10.2 AMENDMENT ONE TO COMMERCIAL MANUFACTURING AGREEMENT This first amendment (the “Amendment”) to that certain Commercial Manufacturing Agreement (the “Agreement”) effective as of February 5, 2013 by and between Pharmacyclics, Inc. a corporation organized under the laws of State of Delaware and having its principal place of address 995 E. Arques Avenue, Sunnyvale, CA 94085 (“Pharmacyclics |
|
| November 19, 2013 |
Commercial Manufacturing Agreement (the “Agreement”) EX-10.1 2 ex101to8k0738011192013.htm Exhibit 10.1 Commercial Manufacturing Agreement (the “Agreement”) by and between Lonza Sales Ltd. Münchensteinerstrasse 38 CH4002 Basel Switzerland - hereinafter “Lonza”- and Pharmacyclics, Inc. 995 E. Argues Avenue Sunnyvale, CA 94085 U.S.A. - hereinafter “Pharmacyclics” - Effective as of February 5, 2013 (the “Effective Date”) [**] Certain information in this |
|
| November 14, 2013 |
Exhibit 99.1 IMBRUVICATM Approval Call 13-Nov-2013 CORPORATE PARTICIPANTS Ramses M. Erdtmann SVP-Investor Relations, Administration, Pharmacyclics, Inc. Robert W. Duggan Chairman & Chief Executive Officer, Pharmacyclics, Inc. Manmeet Singh Soni Executive Vice President-Finance, Pharmacyclics, Inc. Jesse McGreivy MD Chief Medical Officer, Pharmacyclics, Inc. Urte Gayko Senior Vice President-Regulat |
|
| November 14, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2013 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission F |
|
| November 13, 2013 |
Exhibit 99.1 U.S. Food and Drug Administration Approves IMBRUVICATM (ibrutinib) as a Single Agent for Patients with Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy Corporate Conference Call Scheduled Today at 10:00 a.m. PT SUNNYVALE, CA, November 13, 2013 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (i |
|
| November 13, 2013 |
Financial Statements and Exhibits, Other Events - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2013 PHARMACYCLICS, INC. (Exact Name of Registrant as specified in Charter) Delaware 000-26658 94-3148201 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 13, 2013 |
8-K 1 form8k20738011132013.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2013 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction |
|
| November 12, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 form8k07380c11072013.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2013 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction o |
|
| November 12, 2013 |
3rd Quarter, 2013 Earnings Call Exhibit 99.1 3rd Quarter, 2013 Earnings Call 07-Nov-2013 CORPORATE PARTICIPANTS Ramses M. Erdtmann SVP-Investor Relations, Administration, Pharmacyclics, Inc. Robert W. Duggan Chairman & Chief Executive Officer, Pharmacyclics, Inc. Manmeet Singh Soni Executive Vice President-Finance, Pharmacyclics, Inc. Jesse McGreivy MD Chief Medical Officer, Pharmacyclics, Inc. Betty Chang Vice President-Researc |
|
| November 7, 2013 |
Exhibit 99.9 Kinetics of chronic lymphocytic leukemia cells in tissues and blood during therapy with the BTK inhibitor ibrutinib Dominik Wodarz1, Naveen Garg2, Natalia L. Komarova1, Ohad Benjamini3, Michael J. Keating3, William G. Wierda3, Hagop Kantarjian3, Danelle James4, Susan O’Brien3, Jan A. Burger3 1 Departments of Mathematics and Ecology and Evolutionary Biology, University of California, I |
|
| November 7, 2013 |
EX-99.19 20 ex9919to8k07380a11072013.htm Exhibit 99.19 In vivo effects of ibrutinib on the migration of chronic lymphocytic leukemia cells differ between patients and reduce the ability of the bone marrow microenvironment to attract the tumor cells. Sarah E. M. Herman1, Jade Jones1, Rashida Mustafa1, Mohammed Farooqui1, and Adrian Wiestner1 1Hematology Branch, National Heart, Lung and Blood Instit |
|
| November 7, 2013 |
Exhibit 99.13 Clonal evolution in patients with chronic lymphocytic leukemia (CLL) developing resistance to BTK inhibition Jan A. Burger1, Dan A. Landau2,3, Julia Hoellenriegel1, Carrie Sougnez2, Matthias Schlesner4, Naveed Ishaque4, Benedikt Brors4, Michael J. Keating1, William G. Wierda1, Kristian Cibulskis2, Hagop Kantarjian1, Susan O’Brien1, Donna Neuberg5, Thorsten Zenz6, Gad Getz2, Catherine |
|
| November 7, 2013 |
Exhibit 99.11 Ibrutinib differentially interferes with surface IgM and IgD BCR signaling kinetics in Chronic Lymphocytic Leukemia. Elisa ten Hacken1,2, Cristina Scielzo2, William G. Wierda1, Michael J. Keating1, Susan O’Brien1, Paolo Ghia2, Federico Caligaris-Cappio2 and Jan A. Burger1 1 Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX 2 Universita’ Vita-Sal |
|
| November 7, 2013 |
Exhibit 99.14 Single agent Ibrutinib (PCI-32765) achieves equally good and durable responses in chronic lymphocytic leukemia (CLL) patients with and without deletion 17p 1Mohammed Farooqui, DO, 1Georg Aue, MD, PhD, 1Janet Valdez, PA, 1Sabrina Martyr, MD, 1Jade Jones, MS IV, 1Susan Soto, RN, 2Maryalice Stetler-Stevenson, MD, 2Constance Yuan, MD, 2Diane C Arthur, MD, 3Francine Thomas, BS, 4Xin Tian, |
|
| November 7, 2013 |
Ibrutinib (PCI-32765) antagonizes Rituximab-dependent NK-cell mediated cytotoxicity EX-99.22 23 ex9922to8k07380a11072013.htm Exhibit 99.22 Ibrutinib (PCI-32765) antagonizes Rituximab-dependent NK-cell mediated cytotoxicity Holbrook E. Kohrt1, Idit Barfi1, Sarwish Rafiq2, 3, Sarah E. M. Herman3, Jonathon P. Butchar4, Carolyn Cheney3, Xiaoli Zhang5, Joseph J. Buggy6, Natarajan Muthusamy3, Ronald Levy1†, Amy J. Johnson2, 3, 7† and John C. Byrd2, 3, 7† 1. Division of Oncology, Depart |
|
| November 7, 2013 |
Exhibit 99.3 Ibrutinib in Combination with Bendamustine and Rituximab is Active and Tolerable in Patients with Relapsed/Refractory CLL/SLL: Final Results of a Phase 1b Study J.R. Brown1, J. Barrientos2, P. Barr3, I. Flinn4, J. Burger5, Z. Salman6, F. Clow6, D. James6, T. Graef6, J. W. Friedberg3, K. Rai2, S. O’Brien5 1Dana-Farber Cancer Institute, Boston, MA 2Hofstra North Shore-LIJ School of Medi |
|
| November 7, 2013 |
American Society of Hematology (ASH) Annual Meeting Exhibit 99.1 American Society of Hematology (ASH) Annual Meeting: New Orleans, LA; Dec. 7 – 10 Title Presenting Author Status Presentation Date/time The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-term Safety and Durability of Response in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients in an Open-Label Extension Study Dr |
|
| November 7, 2013 |
Exhibit 99.10 Bruton′s Tyrosine Kinase Inhibitor Ibrutinib Interferes With Constitutive and Induced Pre-B Cell Receptor Signaling In B-Cell Acute Lymphoblastic Leukemia Ekaterina Kim, MS1*, Stefan Koehrer, MD1*, Nathalie Y. Rosin, PhD1*, Zhiqiang Wang, Ph.D.2*, Deborah A. Thomas, MD1, Farhad Ravandi, MD1, Steven M. Kornblau, MD1, Hagop M. Kantarjian, MD1, Susan O'Brien, MD1, Zeev Estrov, MD1, Jose |
|
| November 7, 2013 |
Exhibit 99.8 Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk Chronic Lymphocytic Leukemia (CLL): new, updated results of a Phase II trial in 40 patients. Jan A. Burger1, Michael J. Keating1, William G. Wierda1, Julia Hoellenriegel1, Ghayathri Jeyakumar1, Alessandra Ferrajoli1, Stefan Faderl1, Marylou Cardenas1, |
|
| November 7, 2013 |
Exhibit 99.21 Rituximab But Not GA101 Is Partially Antagonistic With Inhibitors Of The B-Cell Receptor Pathway In Diffuse Large B-Cell Lymphoma Anna-Katharina Zoellner1*, Nico Peter2*, Grit Hutter2*, Yvonne Zimmermann2*, Wolfgang Hiddemann, MD1,2 and Martin Dreyling1,2 1Department of Internal Medicine III, University Hospital Munich-Großhadern, Munich, Germany 2Clinical Cooperative Group Leukemia, |
|
| November 7, 2013 |
Exhibit 99.4 Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study in Treatment-Naïve Patients With CD20-Positive B-Cell Non-Hodgkin’s Lymphoma (NHL) Anas Younes,1* Ian Flinn,2 Jesus Berdeja,2 Jonathan W. Friedberg,3 Carla Casulo,3 Catherine Thieblemont,4 Franck Morschhauser,5 Jason Westin,6 Shobha Seetharam,7 |
|
| November 7, 2013 |
Exhibit 99.18 Effective inhibition of tumor microenvironment interactions in CLL patients treated with the BTK inhibitor ibrutinib results in sustained inhibition of tumor proliferation and survival pathways. Sarah E. M. Herman1, Rashida Mustafa1, Sabrina Martyr1, Jennifer Gyamfi1, Janet Valdez1, Susan Soto1, Mohammed Farooqui1, and Adrian Wiestner1 1Hematology Branch, National Heart, Lung and Blo |
|
| November 7, 2013 |
Pharmacyclics, Inc. Condensed Consolidated Balance Sheets (unaudited; in thousands) Exhibit 99.1 Pharmacyclics Reports Third Quarter 2013 Results SUNNYVALE, CA, November 7, 2013 Pharmacyclics, Inc. (the “Company”) (Nasdaq: PCYC) today reported financial results and recent developments for the quarter ended September 30, 2013. Financial Results for the Three and Nine Months Ended September 30, 2013 Revenue for the quarter ended September 30, 2013 was $79.1 million compared to $54. |
|
| November 7, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 pcyc20130930q3x10-q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Com |
|
| November 7, 2013 |
Exhibit 99.12 Longitudinal Gene Expression Profiling Reveals Down-regulation of BCR Signaling-related Genes in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Ibrutinib plus Rituximab Julia Hoellenriegel1, Elena Hartmann2, Andreas Rosenwald2, Susan O’Brien1, Michael J. Keating1, William G. Wierda1, Joseph J. Buggy3, and Jan A. Burger1 1 Department of Leukemia, The University of Texas M.D. |
|
| November 7, 2013 |
Exhibit 99.15 Ibrutinib inhibits B-cell adhesion and causes an efflux of chronic lymphocytic leukemia cells from the tissue microenvironment into the blood leading to a transient treatment-induced lymphocytosis Rashida Z. Mustafa1, Sarah E. M. Herman1, Jade, Jones1, Jennifer Gymafi1, Mohammed Farooqui1, and Adrian Wiestner1 1Hematology Branch, National Heart, Lung and Blood Institute, National Ins |
|
| November 7, 2013 |
Subset of CD4+ T-cells (measured in 10 patients) Exhibit 99.17 Cytokine and T-Cell Phenotypic Changes Upon In Vivo Ibrutinib Therapy For CLL – Targeting Both CLL Cells and The Tumor-Microenvironment Carsten U Niemann, MD, PhD1*, Angelique Biancotto, PhD2*, Betty Y. Chang, PhD3*, Joseph J. Buggy, PhD3*, J. Philip McCoy Jr.4*, Mohammed Farooqui, DO1 and Adrian Wiestner, MD, PhD1 1Hematology Branch, National Heart, Lung, and Blood Institute, Nation |
|
| November 7, 2013 |
EX-99.6 7 ex996to8k07380a11072013.htm Exhibit 99.6 Somatic activating mutations in CXCR4 are common in patients with Waldenstrom’s Macrogloblinemia, and their expression in WM cells promotes resistance to ibrutinib. Yang Cao, Zachary R. Hunter, Xia Liu, Lian Xu, Guang Yang, Christina Tripsas, Robert J. Manning, Christopher J. Patterson, Steven P. Treon. Bing Center for Waldenstrom’s Macroglobuline |
|
| November 7, 2013 |
Exhibit 99.16 In patients with chronic lymphocytic leukemia (CLL) ibrutinib effectively reduces clonal IgM paraproteins and serum free light chains while increasing normal IgM, and IgA serum levels, suggesting a nascent recovery of humoral immunity 1Georg Aue, MD, PhD, 1Mohammed Farooqui, DO, 1Jade Jones, MS IV, 1Janet Valdez, PA, 1Sabrina Martyr, MD, 1Susan Soto, RN, 2Constance Yuan, MD, PhD, 2Ma |
|
| November 7, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2013 PHARMACYCLICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-26658 94-3148201 (State or other jurisdiction of incorporation) (Commission Fi |
